Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Source

Planned Parenthood Federation of America

Contact

Statement from Cecile Richards, President, Planned Parenthood Federation of America

 


UPDATE: The Associated Press is reporting that the FDA panel has approved the HPV vaccine unanimously, and an agency decision is expected by June 8.


New York, NY — Today, a U.S. Food and Drug Administration (FDA) advisory committee is considering whether to recommend approval of the first vaccine against two types of human papilloma virus (HPV) that cause about 70 percent of cervical cancer cases. Each year approximately 10,000 cases of cervical cancer are diagnosed in the United States, and 4,000 American women die from the disease. Worldwide, cervical cancer is the second leading cause of cancer deaths among women.

Planned Parenthood Federation of America applauds the development of the HPV vaccine and urges the FDA to give the product a thorough and expedient review. Cecile Richards, president of Planned Parenthood Federation of America, issued the following statement:

"The HPV vaccine should be a top public health priority for the FDA. It is common sense, good medicine and a groundbreaking step forward in the fight against cancer."

"Each year, Planned Parenthood provides more than 1,000,000 women with cancer screenings aimed at early detection to keep them safe. Availability of an HPV vaccine would give future generations the promise of health, safety, and peace of mind."

Published

May 18, 2006

###

 

Source

Planned Parenthood Federation of America

Contact

 

Gustavo Suarez, 212-261-4339
Erin Kiernon 202-973-4975

Published

May 18, 2006

We and our third partners use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

We, and our third-party partners, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.

Marketing

On

We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.

User Feedback and Session Replay

On

We use qualitative data from LogRocket, UserZoom, Hotjar and AB Tasty to learn about your user experience and improve our products and services. LogRocket allows us to view session replays.